<DOC>
	<DOCNO>NCT02566707</DOCNO>
	<brief_summary>During past year treatment HIV-1 infection transform towards chronic treatment . Patients treated antiretroviral drug many year become old . The risk develop side-effects due long term antiretroviral therapy therefore likely . New alternative once-daily maintenance regime need extensively pre-treated experience side-effects toxicity standard treatment combination . A possible once-daily , fully active maintenance regimen combination atazanavir ( unboosted ) , dolutegravir lamivudine ( PRADAII regimen ) . This combination expect safe , once-daily maintenance regimen favorable side-effect profile . The combination suit patient intolerance and/or resistance NRTIs , NNRTIs ritonavir , suppress viral load . However , new combination pharmacokinetic profile unknown data short-term long-term safety efficacy . This study wille therefore ass pharmacokinetics , safety efficacy small number HIV-1 infected patient .</brief_summary>
	<brief_title>Pharmacokinetics Atazanavir /Dolutegravir/Lamivudine Regimen Maintenance Regimen</brief_title>
	<detailed_description />
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIVinfected document positive HIV antibody test confirm Western Blot . Subject need switch maintenance regimen due adverse effect , toxicity , simplification and/or resistance . Subject least 18 year age day screen . Subject able willing sign Informed Consent Form prior screen evaluation . HIV1 RNA &lt; 40 copies/mL least 6 month antiretroviral therapy prior inclusion . Subject document resistance mutation PIs , INSTIs lamivudine . Documented history sensitivity/idiosyncrasy medicinal product excipients . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . Inability understand nature extent trial procedure require . Pregnant female ( confirm HCG test perform less 3 week first dose ) breastfeed female . Abnormal serum transaminase determine level &gt; 5 time upper limit normal . Renal failure determine estimate Glomerular Filtration Rate ( eGFR ) &lt; 50 ml/min ( MDRDbased ) . Concomitant use medication interfere atazanavir , dolutegravir lamivudine pharmacokinetics : oxcarbazepine , phenytoin , phenobarbital , carbamazepine , St. John 's wort , rifampicin , clarithromycin , H2 receptor antagonist , proton pump inhibitor , irinotecan , midazolam , triazolam , buprenorphine , aprepitant , modafinil , imatinib , cotrimoxazole , antiretroviral drug . Concomitant use medication contraindicate use atazanavir , dolutegravir lamivudine : alfuzosin , dofetilide , pimozide , quetiapine , quinidine , bepridil , simvastatin , atorvastatin , lovastatin , sildenafil ( use pulmonary arterial hypertension ) , cladribine . Active hepatobiliary hepatic disease ( include chronic hepatitis B C infection ) . Alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>